



## Review

# Clinical practice guidelines for *BRCA1* and *BRCA2* genetic testing<sup>☆</sup>



Pascal Pujol <sup>a,b,\*</sup>, Massimo Barberis <sup>c</sup>, Philp Beer <sup>d,e</sup>, Eitan Friedman <sup>f,g</sup>,  
 Josep M. Piulats <sup>h,i</sup>, Ettore D. Capoluongo <sup>j</sup>, Jesus Garcia Foncillas <sup>k</sup>,  
 Isabelle Ray-Coquard <sup>l</sup>, Frédérique Penault-Llorca <sup>m,n</sup>,  
 William D. Foulkes <sup>o</sup>, Clare Turnbull <sup>p,q,r</sup>, Helen Hanson <sup>p</sup>,  
 Steven Narod <sup>s,t</sup>, Banu K. Arun <sup>u</sup>, Matti S. Aapro <sup>v</sup>,  
 Jean-Louis Mandel <sup>w,x</sup>, Nicola Normanno <sup>y</sup>, Diether Lambrechts <sup>z</sup>,  
 Ignace Vergote <sup>aa</sup>, Michèle Anahory <sup>ab</sup>, Bernard Baertschi <sup>ac</sup>,  
 Karen Baudry <sup>a</sup>, Yves-Jean Bignon <sup>ad,ae</sup>, Marc Bollet <sup>af</sup>, Carole Corsini <sup>a</sup>,  
 Olivier Cussenot <sup>ag,ah,ai</sup>, Thibault De la Motte Rouge <sup>aj,ak,al</sup>,  
 Marie Duboys de Labarre <sup>a</sup>, Florence Duchamp <sup>a</sup>, Clarisse Duriez <sup>am</sup>,  
 Karim Fizazi <sup>an</sup>, Virginie Galibert <sup>a</sup>, Laurence Gladieff <sup>ao</sup>,  
 Joseph Gligorov <sup>ap</sup>, Pascal Hammel <sup>aq</sup>, Marion Imbert-Bouteille <sup>a</sup>,  
 William Jacot <sup>ar,as</sup>, Tatiana Kogut-Kubiak <sup>a</sup>, Pierre-Jean Lamy <sup>at</sup>,  
 Sophie Nambot <sup>au,av,aw</sup>, Yann Neuzillet <sup>ax</sup>, Sylviane Olschwang <sup>ay,az</sup>,

<sup>☆</sup> This work was commissioned and supported by the French Society of Predictive and Personalized Medicine (Société Française de Médecine Prédictive et Personnalisée) (grant no. 11SFMP201902), an independent nonprofit learned society.

\* Corresponding author: Department of Cancer Genetics, CHU Montpellier, Univ Montpellier, Montpellier, France.

E-mail addresses: [p-pujol@chu-montpellier.fr](mailto:p-pujol@chu-montpellier.fr) (P. Pujol), [Massimo.barberis@ieo.it](mailto:Massimo.barberis@ieo.it) (M. Barberis), [pbeer@doctors.org.uk](mailto:pbeer@doctors.org.uk) (P. Beer), [Eitan.Friedman@sheba.health.gov.il](mailto:Eitan.Friedman@sheba.health.gov.il) (E. Friedman), [jmpiulats@iconcologia.net](mailto:jmpiulats@iconcologia.net) (J.M. Piulats), [ettoredomenico.capoluongo@unina.it](mailto:ettoredomenico.capoluongo@unina.it) (E.D. Capoluongo), [jesus.garciafoncillas@oncohealth.eu](mailto:jesus.garciafoncillas@oncohealth.eu) (J. Garcia Foncillas), [Isabelle.Ray-Coquard@lyon.unicancer.fr](mailto:Isabelle.Ray-Coquard@lyon.unicancer.fr) (I. Ray-Coquard), [Frederique.PENAULT-LLORCA@cjf.fr](mailto:Frederique.PENAULT-LLORCA@cjf.fr) (F. Penault-Llorca), [william.foulkes@mcgill.ca](mailto:william.foulkes@mcgill.ca) (W.D. Foulkes), [Clare.Turnbull@genomicsengland.co.uk](mailto:Clare.Turnbull@genomicsengland.co.uk) (C. Turnbull), [helen.hanson@icr.ac.uk](mailto:helen.hanson@icr.ac.uk) (H. Hanson), [Steven.Narod@wchospital.ca](mailto:Steven.Narod@wchospital.ca) (S. Narod), [barun@mdanderson.org](mailto:barun@mdanderson.org) (B.K. Arun), [Maapro@genolier.net](mailto:Maapro@genolier.net) (M.S. Aapro), [jmandel@igbmc.fr](mailto:jmandel@igbmc.fr) (J.-L. Mandel), [n.normanno@istitutotumori.na.it](mailto:n.normanno@istitutotumori.na.it) (N. Normanno), [diether.lambrechts@kuleuven.vib.be](mailto:diether.lambrechts@kuleuven.vib.be) (D. Lambrechts), [ignace.vergote@uzleuven.be](mailto:ignace.vergote@uzleuven.be) (I. Vergote), [manahory@pechdelacause.com](mailto:manahory@pechdelacause.com) (M. Anahory), [bernard.baertschi@unige.ch](mailto:bernard.baertschi@unige.ch) (B. Baertschi), [k-baudry@chu-montpellier.fr](mailto:k-baudry@chu-montpellier.fr) (K. Baudry), [Yves-Jean.Bignon@cjf.fr](mailto:Yves-Jean.Bignon@cjf.fr) (Y.-J. Bignon), [marc.bollet@horg.fr](mailto:marc.bollet@horg.fr) (M. Bollet), [c-corsini@chu-montpellier.fr](mailto:c-corsini@chu-montpellier.fr) (C. Corsini), [olivier.cussenot@tnn.aphp.fr](mailto:olivier.cussenot@tnn.aphp.fr) (O. Cussenot), [t.delamotterouge@rennes.unicancer.fr](mailto:t.delamotterouge@rennes.unicancer.fr) (T. De la Motte Rouge), [m-duboydelabarre@chu-montpellier.fr](mailto:m-duboydelabarre@chu-montpellier.fr) (M. Duboys de Labarre), [f-duchamp@chu-montpellier.fr](mailto:f-duchamp@chu-montpellier.fr) (F. Duchamp), [duriez.clarisse@gmail.com](mailto:duriez.clarisse@gmail.com) (C. Duriez), [karim.FIZAZI@gustaveroussy.fr](mailto:karim.FIZAZI@gustaveroussy.fr) (K. Fizazi), [v-galibert@chu-montpellier.fr](mailto:v-galibert@chu-montpellier.fr) (V. Galibert), [Gladieff.Laurence@iuct-oncopole.fr](mailto:Gladieff.Laurence@iuct-oncopole.fr) (L. Gladieff), [joseph.gligorov@aphp.fr](mailto:joseph.gligorov@aphp.fr) (J. Gligorov), [joseph.gligorov@tnn.aphp.fr](mailto:joseph.gligorov@tnn.aphp.fr) (J. Gligorov), [pascal.hammel@bjn.aphp.fr](mailto:pascal.hammel@bjn.aphp.fr) (P. Hammel), [m-imbertybouteille@chu-montpellier.fr](mailto:m-imbertybouteille@chu-montpellier.fr) (M. Imbert-Bouteille), [William.Jacot@icm.unicancer.fr](mailto:William.Jacot@icm.unicancer.fr) (W. Jacot), [t-kogutkubiak@chu-montpellier.fr](mailto:t-kogutkubiak@chu-montpellier.fr) (T. Kogut-Kubiak), [pierre-jean.lamy@labosud.fr](mailto:pierre-jean.lamy@labosud.fr) (P.-J. Lamy), [sophie.nambot@chu-dijon.fr](mailto:sophie.nambot@chu-dijon.fr) (S. Nambot), [y.neuzillet@hopital-foch.org](mailto:y.neuzillet@hopital-foch.org) (Y. Neuzillet), [solschwang@gmail.com](mailto:solschwang@gmail.com) (S. Olschwang), [xavier.rebillard@wanadoo.fr](mailto:xavier.rebillard@wanadoo.fr) (X. Rebillard), [jm-rey@chu-montpellier.fr](mailto:jm-rey@chu-montpellier.fr) (J.-M. Rey), [c-rideau@chu-montpellier.fr](mailto:c-rideau@chu-montpellier.fr) (C. Rideau), [jean-philippe.spano@psl.aphp.fr](mailto:jean-philippe.spano@psl.aphp.fr) (J.-P. Spano), [frederic.thomas2@ird.fr](mailto:frederic.thomas2@ird.fr) (F. Thomas), [isabelle.treilleux@lyon.unicancer.fr](mailto:isabelle.treilleux@lyon.unicancer.fr) (I. Treilleux), [marion.vandromme@gmail.com](mailto:marion.vandromme@gmail.com) (M. Vandromme), [j-vendrell@chu-montpellier.fr](mailto:j-vendrell@chu-montpellier.fr) (J. Vendrell), [michelevintraud@live.fr](mailto:michelevintraud@live.fr) (M. Vintraud), [daniel.zarca@gmail.com](mailto:daniel.zarca@gmail.com) (D. Zarca), [kshughes@partners.org](mailto:kshughes@partners.org) (K.S. Hughes), [jealesm@yahoo.es](mailto:jealesm@yahoo.es) (J.E. Alés Martínez).

<https://doi.org/10.1016/j.ejca.2020.12.023>

0959-8049/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Xavier Rebillard<sup>ba</sup>, Jean-Marc Rey<sup>a</sup>, Chloé Rideau<sup>a</sup>,  
 Jean-Philippe Spano<sup>bb,bc</sup>, Frédéric Thomas<sup>bd</sup>, Isabelle Treilleux<sup>be</sup>,  
 Marion Vandromme<sup>am</sup>, Julie Vendrell<sup>bf</sup>, Michèle Vintraud<sup>bg</sup>,  
 Daniel Zarca<sup>bh</sup>, Kevin S. Hughes<sup>bi</sup>, Jose E. Alés Martínez<sup>bj</sup>

<sup>a</sup> Department of Cancer Genetics, CHU Montpellier, Univ Montpellier, Montpellier, France

<sup>b</sup> CREEC, UMR IRD 224-CNRS 5290 Université Montpellier, Montpellier, France

<sup>c</sup> Pathology Unit, European Institute of Oncology, Milan, Italy

<sup>d</sup> Wellcome Trust Sanger institute, Cambridge, United Kingdom

<sup>e</sup> Glasgow Precision Oncology Laboratory, United Kingdom

<sup>f</sup> The Susanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Ramat Gan, Israel

<sup>g</sup> Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel

<sup>h</sup> Unidad Funcional de Cáncer de Próstata, Servicio de Oncología Médica, Hospital Universitari de Bellvitge-Institut Català d'Oncologia (ICO), Hospitalet de Llobregat, Spain

<sup>i</sup> Servicio de Oncología Médica, Institut Català d'Oncologia (ICO), Hospitalet de Llobregat, Spain

<sup>j</sup> Dipartimento di Medicina Molecolare e Biotecnologie Mediche Università Federico II, CEINGE Biotecnologie Avanzate, Naples, 80145, Italy

<sup>k</sup> Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jimenez Diaz-UAM, Madrid, Spain

<sup>l</sup> Oncologie Médicale, Centre Leon Bérard; Univ Lyon, Université Claude Bernard Lyon1, Hesper EA 7425, F - 69003, Lyon, France

<sup>m</sup> Department of Biology and Pathology, Centre Jean Perrin, Clermont Ferrand, France

<sup>n</sup> UMR INSERM 1240, Université Clermont Auvergne, Clermont Ferrand, France

<sup>o</sup> McGill University, Division of Medical Genetics, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

<sup>p</sup> Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK

<sup>q</sup> Genomics England, Queen Mary University of London, London, UK

<sup>r</sup> Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK

<sup>s</sup> University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada

<sup>t</sup> Canada Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada

<sup>u</sup> Anderson Cancer Center, The University of Texas, Department of Breast Medical Oncology, Division of Cancer Medicine, USA

<sup>v</sup> IMO Clinique de Genolier, Genolier, Switzerland

<sup>w</sup> Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France

<sup>x</sup> Université de Strasbourg, Illkirch, France

<sup>y</sup> Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy

<sup>z</sup> Laboratory of Translational Genetics (VIB-KU Leuven), ON IV Herestraat 49 – box 912, 3000, Leuven Belgium

<sup>aa</sup> Department of Gynaecologic Oncology University Hospitals Leuven, Gasthuisberg Herestraat 49, 3000 Leuven, Belgium

<sup>ab</sup> Pech de Laclause, Bathmanabane & Associés Law Firm, Paris, France

<sup>ac</sup> French National Institute for Health and Medical Research (INSERM) Ethics Committee, France University of Geneva, Geneva, Switzerland

<sup>ad</sup> Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France

<sup>ae</sup> INSERM-U1240-Molecular Imaging and Theranostic Strategies (IMOST), Clermont-Ferrand, France

<sup>af</sup> Institut Hartmann, 4, rue Kléber, et Institut Rafael, 3 bd Bineau, 92309 Levallois-Perret cedex, France

<sup>ag</sup> CeRePP, Hopital Tenon, Paris, France

<sup>ah</sup> Sorbonne Université, Institut Universitaire de Cancérologie, GRC n°5 ONCOTYPE-URO, Hopital Tenon, APHP, Paris, France

<sup>ai</sup> Department of Urology, Assistance Publique- Hôpitaux de Paris, Hopital Tenon, Paris, France

<sup>aj</sup> Inserm, Oncogenesis, Stress and Signaling, 35000 Rennes, France

<sup>ak</sup> Service d'oncologie médicale, CRLCC Eugène-Marquis, 35000 Rennes, France

<sup>al</sup> UMR 1242, Inserm, Univ Rennes, CLCC Eugène Marquis, Rue Bataille Flandres Dunkerque, 35042, Rennes, France

<sup>am</sup> BRCA France Association, France

<sup>an</sup> Institut Gustave Roussy and University of Paris Sud, Villejuif, France

<sup>ao</sup> Department of Medical Oncology, Institut Claudius Regaud, IUCT-O, Toulouse, France

<sup>ap</sup> APHP-Tenon, IUC-UPMC, Sorbonne University, Paris, France

<sup>aq</sup> Department of Pancreatology, Hôpital Beaujon (AP-HP), Université Denis Diderot-Paris VII, Clichy, France

<sup>ar</sup> Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, 208 rue des Apothicaires, 34298, Montpellier Cedex 5, France

<sup>as</sup> Translational Research Unit, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France

<sup>at</sup> Institut d'analyse génomique-Imagénome, Labosud, Montpellier, France

<sup>au</sup> Centre de Génétique et Centre de Référence Maladies Rares (Anomalies du Développement de l'Interrégion Est), Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France

<sup>av</sup> Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France

<sup>aw</sup> Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne et Université de Bourgogne-Franche Comté, Dijon, France

<sup>ax</sup> Service d'urologie et de transplantation rénale, hôpital Foch, université de Versailles - Saint-Quentin-en-Yvelines, 40, rue Worth, 92150 Suresnes, France

<sup>ay</sup> Aix Marseille Université, INSERM GMGF UMR 1251, France

<sup>az</sup> Département de Génétique Médicale, Hôpital Européen & Groupe Ramsay Générale de Santé, Hôpital Clairval, Aix Marseille Université, Marseille, France

<sup>ba</sup> Service d'Urologie, Clinique Beausoleil, Montpellier, France

<sup>bb</sup> Department of Medical Oncology, Hôpital Pitié Salpêtrière, APHP, Sorbonne Université, Paris, France

<sup>bc</sup> Inserm UMRS 1136, Sorbonne Université, Paris, France

<sup>bd</sup> IRD, CREEC et MIVE911 avenue Agropolis, BP 64501, Montpellier 34 394, France

<sup>be</sup> Department of Pathology, Centre Léon Bérard, 28 rue Laënnec, 69373, Lyon Cédex 08, France

<sup>bf</sup> IRCM, INSERM 1194, Department of Pathology and Oncobiology, Laboratoire de biologie des tumeurs solides, CHU Montpellier, Univ Montpellier, Montpellier, France

<sup>bg</sup> Department of Radiotherapy, Hartmann Radiotherapy Center, Levallois-Perret, France

<sup>bh</sup> The Paris Breast Centre- L'Institut Français du Sein- 15 rue Jean Nicot, 75007, Paris, France

<sup>bi</sup> Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

<sup>bj</sup> Medical Oncology Department, Hospital Nuestra Señora de Sonsoles, Ávila, Ávila, Spain

Received 23 October 2020; received in revised form 9 December 2020; accepted 14 December 2020

Available online 10 February 2021

## KEYWORDS

BRCA1 and BRCA2 testing;  
Guidelines;  
BRCA-related cancer;  
PARP inhibitors

**Abstract** *BRCA1 and BRCA2* gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now overlap with both preventive and therapeutic management, updated and comprehensive practice guidelines for BRCA genotyping are needed.

The integrative recommendations for BRCA testing presented here aim to (1) identify individuals who may benefit from genetic counselling and risk-reducing strategies; (2) update germline and tumour-testing indications for PARPi-approved therapies; (3) provide testing recommendations for personalised management of early and metastatic breast cancer; and (4) address the issues of rapid process and tumour analysis.

An international group of experts, including geneticists, medical and surgical oncologists, pathologists, ethicists and patient representatives, was commissioned by the French Society of Predictive and Personalised Medicine (SFMPP). The group followed a methodology based on specific formal guidelines development, including (1) evaluating the likelihood of BRCAm from a combined systematic review of the literature, risk assessment models and expert quotations, and (2) therapeutic values of BRCAm status for PARPi therapy in BRCA-related cancer and for management of early and advanced breast cancer.

These international guidelines may help clinicians comprehensively update and standardise BRCA testing practices.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

*BRCA1 and BRCA2* genes (BRCA) analysis is increasingly being used to detect pathogenic variants for both preventive and therapeutic issues. Several guidelines on BRCA testing are available worldwide, but recent therapeutic advances in breast cancer management and approved therapies with poly(ADP)ribose polymerase inhibitor (PARPi) agents in breast, ovarian, prostate and pancreatic cancers, as well as the specific rapid

germline and tumour testing process, deserve a comprehensive and integrative update to optimise BRCA testing in clinical practice.

BRCA pathogenic or likely pathogenic variants (mutations, BRCAm) account for most identifiable hereditary breast and ovarian cancer (HBOC) syndromes. For women who carry a BRCAm, the cumulative risk for developing breast or ovarian cancer by age 70 years is 45%–66% and 11%–41%, respectively [1,2]. Validation of screening and preventive strategies in BRCAm

carriers and increased awareness of their benefit by population and healthcare providers has led to a continuous increase in BRCA testing over the last two decades [3–5]. Thus, we need to update and prioritise the main indications for BRCA testing for breast and ovarian cancer risk assessment based on a rational analysis of the likelihood of BRCAM (IBRCAM).

The major benefit of PARPi therapy for newly diagnosed ovarian cancer combined with improved progression-free survival in advanced ovarian, breast, prostate and pancreatic cancers [6,7] has prompted the development of BRCAM detection for targeted therapies. In some situations, such as ovarian cancer or prostate cancer, detecting somatic mutations has been effective for identifying PARPi-sensitive patients [8]. In breast and pancreatic cancer, only germline mutations can drive an approved PARPi treatment to date. Thus, germline BRCA (gBRCA) and tumour BRCA (tBRCA) mutational analyses are being used for selecting patients who could benefit from a PARPi. In addition, in newly diagnosed breast cancer and metastatic breast cancer, BRCAM status can also lead to a major change in management such as personalised surgery or chemotherapy regimen. These clinical decisions based on BRCAM status need to be performed quickly, guided by tumour type and disease stage. Thus, we need specific guidelines that take into account the clinical applications of BRCAM analysis, as well as tumour and fast-track testing processes.

More than 30 guidelines on BRCA testing are available worldwide [7,9,10]. In the United States, the US National Comprehensive Cancer Network [11], the American Society of Clinical Oncology [6,12] and the US Preventive Services Task Force [13] have published policy statements for genetic testing for BRCA-related cancer. Sixteen different guidelines exist in Europe [7,9,10]. However, most guidelines do not represent international consensus, differ from each other in the IBRCAM threshold retained (10% [14,15] or 5% [11]) and may not integrate the recent need for BRCA genotyping for PARPi treatment and personalised breast cancer management.

Integrated and updated guidelines would optimise and harmonise healthcare offerings of the BRCA testing and the identification of BRCAM carriers for both preventive and therapeutic purposes. Thus, we developed BRCA testing guidelines at an international level with a specific methodology of evaluating the IBRCAM for a given set of criteria. The methodology was based on a combined approach of literature review, expert evaluation and risk model assessment, taking into account newly developed PARPi agents, as well as personalised management of breast cancer.

## 2. Methods

### 2.1. Guideline development and composition of the working group

These guidelines were commissioned by the French Society of Predictive and Personalised Medicine (SFMPP) from September 2019 to June 2020, and a guideline chair was selected (supplementary data). The SFMPP is an independent non-profit learned society with public funding that aims to provide guidelines for genetic testing [16–18]. A Guideline Development Group (GDG) was selected to ensure a wide range of expertise across all relevant disciplines in different countries. Members of the GDG completed a Declaration of Conflict of Interests (CoIs) form (supplementary data), which was reviewed and vetted by the SFMPP. A scoping meeting was held on 5 October 2019 to develop key priorities and validate the methodology described below. Key questions to cover included What are the current indications for BRCA testing in clinical practice? What is the place for BRCA tumour testing and a fast-track process for personalised treatment of BRCA-related cancer? The specific guidelines process is described in [supplementary data](#) and based on published data on IBRCAM and their respective levels of evidence, evaluation of IBRCAM by risk model assessment and expert estimation, and the therapeutic value of BRCAM for managing breast cancer and treating BRCA-related cancer with PARPi agents.

The GDG consisted of a group of 48 multidisciplinary experts from Belgium, England, France, Germany, Italy, Israel, Scotland, Spain, and Switzerland, who were divided into two working subgroups: preventive and therapeutic ([supplementary data](#)). The preventive subgroup included medical geneticists and genetic counsellors, organ specialists, oncologists, surgeons, patient representatives, ethicist experts, psychologists and lawyers. The group also included a methodologist with expertise in evidence appraisal and guideline development. This group provided guidelines and ethical reflection for updating BRCA testing for preventive purposes. The therapeutic subgroup included medical, radiation and surgical oncologists; organ specialists; clinicians and molecular geneticists; pathologists; and patient representatives and provided an independent evaluation of the indication for a PARPi and personalised management of breast cancer.

Experts from the preventive and therapeutic subgroups were invited to evaluate the level of evidence and to estimate by quotation the IBRCAM independently, as described below ([Tables 1a, 1b and 1c](#)). Eight teleconference/webinar meetings were organised to develop this formal consensus and achieve expert agreement. Fourteen additional international experts (listed in

supplementary data) reviewed and proofread recommendations. The overall guideline-development process, including the funding of the work, panel formation, management of CoIs, internal and external review and organisational approval, was guided by procedures derived from the Guidelines International Network–McMaster Guideline Development Checklist [19] and was intended to meet recommendations by the Guidelines International Network [20].

2.2. Parameters evaluated

The IBRCAM for a given criterion was based on a combined approach of literature review, expert quotation and risk model assessment as defined below. The process of development of the guidelines is presented in supplementary data. Current clinical criteria for genetic testing were obtained from existing guidelines (for review, see Refs. [7,9,10]). Criteria were divided into four categories: (1) personal, (2) family or personal and family combined, and (3) theragnostic and (4) personalised management of breast cancer. Whenever possible, a given criterion was evaluated by subcategories (i.e., age at diagnosis: <35, <40, <45, <50 years, any age), and respective data on IBRCAM were collected from the literature. A theragnostic indication was defined as an approved use of PARPi in BRCA-related cancer by continental drug agencies in the United States (US Food and Drug Administration [FDA]) and Europe (European Medicines Agency [EMA]).

2.3. Literature selection process

The search strategy is given in supplementary data. The PubMed database was searched for English language studies published in English from January 1995 to May 2020 by using the following query of terms related to BRCA clinical testing: ((gene, BRCA 1[MeSH]) OR (gene, BRCA 2[MeSH]) OR (BRCA 1 gene[MeSH]) OR (BRCA 2[MeSH]) OR (BRCA1 2[MeSH]) OR (breast cancer 1 gene[Tw]) OR (breast cancer 2 gene[tw]) OR (BRCA1/2[MeSH])) AND ((genetic testing[MeSH]) OR (genetic counselling[MeSH]) OR (genetic risk[MeSH]) OR (breast cancer[MeSH]) OR (ovarian cancer[MeSH]) OR (prostate cancer[MeSH]) OR (pancreatic cancer

Table 1a  
Likelihood of BRCA1 or BRCA2 mutation.

Class	IBRCAM
A	≥10%
B	≥7.5 to <10%
C	≥5 to <7.5%
D	≥2.5 to <5%
E	<2.5%

IBRCAM, likelihood of BRCA1 or BRCA2 pathogenic or likely pathogenic variant.

Table 1b  
Level of evidence.

Level	Definition	Commentary
I	Concordant data on the IBRCAM available in level 1 publication	Level 1 publication: prospective or large retrospective studies, cohort studies with control, pooled studies
II	Data available in level 2 publication or discordant data in the literature	Level 2 publication: cohort study with non-contemporaneous control, case–control series, subgroup analysis
III	Data available in level 3 publication	Level 3 publication: case series without control, small series, series with selection bias
IV	No data available in the literature	Only model assessment of risk available

Table 1c  
Grade of recommendations.

Grade	Definition	Recommendation
A	High IBRCAM (≥7.5%, supported by LOE I/II) and/or therapeutic value	Recommended
B	Moderate IBRCAM (2.5–7.5%) and no therapeutic value	Considered
C	Low IBRCAM (<2.5%) and no therapeutic value	Not routinely proposed

LOE, level of evidence.

[MeSH]) OR (melanoma[MeSH]) OR (cholangiocarcinoma[MeSH]) OR (familial risk[Tw]) OR (prevalence[MeSH]) OR (unselected[Tw]) OR (general population[Tw]) OR (early onset[Tw]) OR (triple negative breast cancer[Tw]) OR (bilateral breast cancer[Tw]) OR (male breast cancer[Tw]) OR (founder effect[Tw]) OR (parp inhibitor[Tw]) OR (poly-adt-ribose polymerase inhibitor[Tw]) OR (polyadenosine diphosphate-ribose polymerase inhibitor[Tw]) OR (platinum sensitive[Tw]) OR (breast cancer management[Tw]) OR (rapid testing[Tw]) OR (fast testing[Tw]) OR (fast track process[Tw]) OR (tumour testing[Tw]) OR (somatic testing[Tw])) AND (English[Language]) AND ('1995/01/01'[Date - Publication]; '2020/06/20'[Date - Publication]) NOT (case reports[Publication Type]) NOT (case reports[Tiab]) NOT (mice[Tw]).

The literature search used variations and Boolean connectors of key terms. Results of database searches were supplemented with bibliographies of seminal articles or reviews and contributions from expert panel members. For guidelines, the websites of associations, colleges and learned societies listing various recommendations were also searched.

A total of 4725 results were found. From these, 603 records were retrieved, including 277 publications retained for estimating IBRCAM and 32 publications or electronic links to guidelines (Supplementary data).

## 2.4. Criteria of evaluation

Criteria for BRCA testing were obtained from existing guidelines and divided into three categories: personal criteria, family or personal and family combined criteria and therapeutic criteria. For each retained criterion, the reported IBRCAM was searched in the literature (as an independent variable or from subgroup analysis). Classes a-e were considered and corresponded to IBRCAM  $\geq 10\%$ ,  $\geq 7.5$  to  $< 10\%$ ,  $\geq 5$  to  $< 7.5\%$ ,  $\geq 2.5$  to  $< 5\%$ , and  $< 2.5\%$ , respectively (Table 1a). The working group defined the level of evidence (LOE) as I, concordant data on the IBRCAM available in level 1 publications; II, data on the IBRCAM available in level 2 publications or discordant data in the literature; III, data on the IBRCAM available in level 3 publications; or IV, no data available, risk model assessments of IBRCAM (Table 1b). The level of publication was defined as 1, prospective or large retrospective studies, cohort studies with control, pooled studies; 2, cohort study with non-contemporaneous control, case–control series, subgroup analysis; or 3, case series without control, small series, series with selection bias (Table 1b).

## 2.5. Model estimation of IBRCAM and expert quotation

The estimation of the IBRCAM was based ideally on existing literature taking into account the level of publication defined above. In some situations, data from the literature were available from studies, including a small number of cases with possible selection bias. Subgroup analysis and model assessment of IBRCAM provided an additional estimation of the IBRCAM. In this study, we used the risk models BRCAPRO [21,22], BOADICEA [23,24], and PennII [25], and their updated versions to estimate the IBRCAM. The estimations were computed with the same fictional pedigree, representative of an average family, described and previously published [3] (also see supplementary data for ‘standard’ pedigree). Data are available in supplementary data.

Experts were invited to estimate the grade of IBRCAM (A-C; see below) in their field of expertise in light of data from the literature by using the a-e classification of the IBRCAM and risk model estimations. The IBRCAM for each criterion was assigned a quotation by at least three independent experts. Experts were also invited to determine the LOE and evaluate the level of publication. Discrepancies in the evaluation were discussed with the steering committee.

## 2.6. Theragnostic value, treatment personalisation

For PARPi, the criteria for recommendations were (1) approval by the EMA and/or FDA and (2) temporary authorisation for use in European countries and breakthrough therapy designation by the FDA. Recommendations for addressing metastatic cancer

(platinum-containing regimen, PARPi, BRCA testing) were based on guidelines from the ABC global alliance in Europe (ABC4 [26], ABC5 [27]) and US ASCO guidelines [12].

## 2.7. Grading recommendations

Guidelines were divided into three grades: grade A, for patients for whom testing should be offered, given a high IBRCAM ( $\geq 7.5\%$  with LOE I or II and/or established therapeutic value); grade B, for patients for whom testing should be considered, given a moderate IBRCAM (2.5–7.5%); and grade C, for patients for whom testing should not be routinely offered, given a low IBRCAM ( $< 2.5\%$ ) (Table 1c).

In this work, the cutoff for a high IBRCAM was set at 7.5%, whereas some guidelines used a threshold of 10% (ASCO [6], NICE [15]) and others 5% (NCCN [11]). With a cutoff of 10%, most of the family criteria would not be considered at high risk (see results section) and most of the criteria analysed to give a IBRCAM of 5%–10%, so the GDG retained the intermediate cutoff of 7.5%. In some subgroups, although the IBRCAM could be above this cutoff, a grade B recommendation was attributed when the LOE was III or IV or when only one study was available.

## 3. Results

### 3.1. Single or personal criteria related to breast cancer

Personal criteria related to breast cancer, including age at disease onset, triple-negative breast cancer (TNBC) phenotype, bilaterality, male breast cancer and founder effect, have been extensively studied, and the IBRCAM are given by subgroups (Table 2a). Only three criteria featured a IBRCAM  $\geq 7.5\%$  with both LOE I and expert quotation of grade A: age  $\leq 40$ , TNBC  $\leq 60$  and male breast cancer. The criterion ‘bilateral breast cancer with first cancer at age  $\leq 50$ ’ was also associated with IBRCAM  $\geq 7.5\%$ , with LOE II and expert quotation grade A. Risk model estimation is in supplementary data (Table S7a).

Age at breast cancer onset  $< 45$  or  $< 50$  years was associated with a wide range of IBRCAM depending on the study (from 1.6% to 12.2% and 4% to 12.4%, respectively). The LOE for these criteria was II and expert quotation grade B.

In women from populations with a small spectrum of founder mutation, with a founder effect (e.g., Ashkenazi, Icelandic, Polish and French-Canadian), the IBRCAM in the literature varied widely when breast cancer was diagnosed at any age. In women with Ashkenazi or Icelandic heritage, the IBRCAM was 4.5%–11.7% and 7.7%–10.3%, respectively. However, most of these studies did not reach LOE I, and the effect

of family history or age in women undergoing a genetic test could not be ruled out. IBRCAM was significantly higher when comparing subgroups of early-onset and male breast cancer with other populations (Ashkenazi heritage, 19.5%–43% and 6.4%–19.1% for early-onset and male breast cancer, respectively; Icelandic heritage, 7.7%–10.3% and 40%, respectively). For Ashkenazi women, breast cancer at age  $\leq 50$  years was associated with a IBRCAM of 8.7%–18.7% with LOE II and expert quotation grade A.

### 3.2. Family and combined criteria

For family and combined criteria, most available data on IBRCAM were noted in the subgroup analysis of cohort and retrospective studies. In many situations, owing to the complexity and a high number of combinations of criteria, data are lacking. The LOE was III or IV for most family or combined criteria, except for ‘the number of cases of breast cancer in  $\geq 2$  relatives’, with LOE II (Table 3a). Risk model estimation is in supplementary data. In several situations, models could not discriminate the specific IBRCAM with combined criteria. In women with breast cancer and a relative with grade A personal criteria (such as early-onset, male breast cancer and ovarian cancer), prediction of IBRCAM by models and expert opinion favoured a grade A recommendation for the first-degree relative and grade B recommendation for second- or third-degree relatives. For any family or combined criteria, Ashkenazi or Icelandic heritage should be taken into account because studies found an increased risk with this heritage. The IBRCAM in women with breast cancer

and a relative with prostate or pancreatic cancer varied widely by study and model, with LOE III-IV and expert estimate grade B.

### 3.3. Treatment personalisation of breast cancer

For women with a recent diagnosis of primary breast cancer and those with metastatic breast cancer, the knowledge of BRCA mutation status could significantly influence the medical or surgical decision-making. Table 4 summarises the situations in which rapid testing could have meaningful clinical application.

For women with primary breast cancer and high IBRCAM, the knowledge of the mutation status may be critical in the surgical options offered, specifically when the patient is a candidate for total mastectomy (uni- or bilateral) because of increased risk of a second ipsi- and/or contralateral cancer. Women with putative hereditary risk, particularly in the context of a strong family history, TNBC, young age at disease onset, or known BRCA mutation in a relative and willing to consider preventive surgery, should receive complete information delivered by a surgeon, oncologist and genetics counsellor to guide their autonomous choice. Prognostic factors of breast cancer, age, comorbidities and psychological aspects should be taken into account, as stated in currently available guidelines (NCCN [11], French Institut National du Cancer 2017 [12,28]). The working group recommended proposing the test in a rapid turnaround time after information on the benefit and risk of prophylactic surgery is given by a multidisciplinary team, including a surgeon, geneticist and medical oncologist if the patient actively opts for this

Table 2a  
IBRCAM according to individual criteria related to breast cancer.

Criteria	IBRCAM* (%)	References	Guidelines	LOE	Quotation*
<b>Age</b>					
$\leq 35$	<b>6–20</b>	1,2,3,4,5,6,7,8,9,10,11,12	13,14,15,16,17,18	<b>I</b>	<b>A</b>
$\leq 40$	<b>3.8–23</b>	5,19,20,21,22,23,24,25,26,27,28,29,30	31,32,33,16,33,34,35	<b>I</b>	<b>A</b>
$\leq 45$	<b>1.6–12.2</b>	5,23,36,37,38,39,40	41,42,43	<b>II</b>	<b>B</b>
$\leq 50$	<b>4–12.4</b>	26,27,44,45,46,47,48	41,49,50,51	<b>II</b>	<b>B</b>
$\leq 55$	<b>2</b>	5		<b>III</b>	<b>C</b>
$> 50$	<b>1.2</b>	52,53,54		<b>III</b>	<b>C</b>
Any age	<b>0.4–7.5</b>	55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,27,54,71,36,72,73,74,75,76,48	None	<b>II</b>	<b>C</b>
<b>TNBC</b>					
$\leq 40$	<b>23–36</b>	77,20,78	31,18	<b>I</b>	<b>A</b>
$\leq 50$	<b>7.6–27.6</b>	79,80,81,77,82	83,16	<b>I</b>	<b>A</b>
$\leq 60$	<b>11.4–16.8</b>	80,78	42,41,84,49,15,14,50	<b>II</b>	<b>A</b>
$> 60$	<b>4.9–5.7</b>	80,85,78,86		<b>II</b>	<b>B</b>
Any age	<b>2.9–17.5</b>	36,87,78,82,88	43	<b>II</b>	<b>B</b>
<b>Bilateral</b>					
1st $\leq 40$	<b>26.7–33.3</b>	25,89,90,24	16	<b>II</b>	<b>A</b>
1st $\leq 50$	<b>9–22.7</b>	91,6,92	32,41,31,33,14,15	<b>II</b>	<b>A</b>
1st $\leq 60$	<b>15.3 (&lt; 55)</b>	93	43,49	<b>III</b>	<b>C</b>
Any age	<b>6.6–34</b>	6,94,20,95,25,96,97,98,89,90	33,99,31,50	<b>III</b>	<b>C</b>
Male	<b>7.4–33</b>	100,101,102,103,104,105,106,107,108,109,110,111	41,32,43,99,112,31,50,18,14	<b>I</b>	<b>A</b>

\* IBRCAM, likelihood to detect BRCA pathogenic or likely pathogenic variant; LOE, level of evidence; TNBC, triple-negative breast cancer.

Table 2b  
IBRCAM according to founder effects.

Criteria	IBRCAM* (%)	References	Guidelines	LOE	Quotation
<b>Ashkenazi heritage</b>					
No cancer	1.1–2.9	1,2,3,4,5,6,7,8,9,10,11,12		I	C
Unselected breast cancer	4.5–25	13,14,15,16,17,18,19,20,21,22,23	24,25,26,27,28,29,30,31,32,33	I	B
Early onset ≤40	19.5–43.3	14,15,17,18,21,34,35,36		I	A
≤50	8.7–18.7	14,37	38	I	A
Male BC	6.4–19.1	37,39,40,41		I	A
Ovarian cancer	35.7–62	18,42,43		II	A
<b>Icelandic heritage</b>					
No cancer	0.4–0.6	44,45		II	C
Unselected BC	7.7–10.4	44,45,46,47,48	29	II	B
Male BC	38–40	46,47,49		II	A
<b>Polish heritage</b>					
No cancer	0.25–0.4	50,51		III	C
Unselected BC	3.1	51		III	B
BC age > 50	8.3	50		III	B
BC age < 50	6–13	52,50		III	B
TNBC	9.9	53		III	B
Unselected ovarian cancer	6.3–21	54,55,56,57,58,59		II	A
<b>French-Canadian heritage</b>					
No cancer	0.2	60,61		II	C
Unselected BC	3.1–3.8	60,63		II	B
BC age < 40	13	64		II	A
BC age < 45	9.3	60		III	B
BC age < 50	4.7–5.1	61,62		II	B
BC and FH	45	65		II	A
Unselected OC	7.7–8	66,67,68		II	A
<b>Hungarian heritage</b>					
BC	3.6	69,70		III	B
BC and FH	18			III	B
OC	11			II	A
<b>Mexican heritage</b>					
TNBC < 50	23	71,72		III	B
BC and FH	6			III	B

\* IBRCAM, likelihood to detect BRCA pathogenic of likely pathogenic variant; LOE, level of evidence; BC, breast cancer; FH, family history; OC, ovarian cancer.

analysis. For patients with newly diagnosed breast cancer and high IBRCAM, breast conservative surgery is also an option [12]. Thus, conservative surgery and uni- or bilateral risk-reducing mastectomy should be discussed and balanced in discussion with the patient, considering the increased risk of a second cancer (ipsi- or contralateral), the physical and psychological burden of surgery and taking into account prognostic factors, age and comorbidities with respect to the autonomous choice of the patient.

For women with breast cancer at low risk of recurrence, such as age at onset >40 years and N0, T1/T2, hormone-receptor–positive (HR+), and human epidermal growth factor receptor–negative (HER2-) tumours, radiation therapy could be omitted when the patient opts for mastectomy rather than conservative surgery for preventive action. In contrast, a risk-reducing mastectomy that follows conservative surgery plus radiation therapy may negatively affect the cosmetic results and increase surgery complications.

In the metastatic setting, for patients with HER2 negative tumours requiring chemotherapy, gBRCA

testing is recommended because a platinum treatment should be preferred to taxane in platinum-naïve patients [12,26,27,29]. In the neoadjuvant setting, because available studies are not conclusive, the use of a platinum-containing regimen is not routinely recommended outside clinical trials (Table 4).

### 3.4. Theragnostic value for PARPi

The use of PARPi and the IBRCAM in breast, ovarian, prostate and pancreatic cancer are summarised in Tables 5 and 6. In ovarian cancer, the benefits of various PARPi therapies (olaparib, niraparib, rucaparib, and veliparib) on progression-free survival in phase III randomised trials are highly significant and approved by the EMA and FDA (Table 5). In the absence of gBRCAm, BRCAm should be screened in any non-mucinous high-grade epithelial ovarian carcinoma at the germline and tumour level because PARPi has been found efficacious in exclusive tumour mutation, and thus, approved by drug agencies (for review, see Ref. [7]). Personal or family criteria could not



Table 3a  
PBRCA in according to family and combined criteria.

Family/combined <sup>‡</sup> criteria	IBRCAM literature (%)	IBRCAM models*(%)	References	Existing guidelines	LOE	Quotation
<b>1 case of BC with 2 cases of BC in a CR**</b>				1,2,3,4,5,6,7,8,9,10	II	A
<b>Any CR</b>	3.8–10.6		11,12,13,14			
1st/1st	13	0.2–10.5	12		III	A
1st/2nd	6	0.1–7	12		III	B
2nd/2nd	4	<0.1–6	12		III	B
<b>1 case of BC and 1 of BC in CR with one age ≤ 50</b>	4–22		11,12,13,15,16,17,18	2,19,20,21,22,6	II	A
1st		0.2–3.8				
2nd		<0.1–3.8				
<b>1 case of BC and bilateral BC in a CR</b>	12.8–21 (age <50)		11,13	19 (first age <50),20,23 (both age <60)	III	A
1st		5–8				
2nd		1.1				
<b>1 case of BC and a CR with ovarian cancer</b>	4.3–55		11,12,13,14,15,16,18	21,20,9,23,19,24,22,2,3,25,5,6,26	II	A
1st		0.4–8				
2nd		<0.1–4.				
<b>1 case of BC and a CR with one male BC</b>	16.5		11	2,19,24,20,23,22,9,6,27,28	II	A
1st		1.2–14				
2nd		0.3–7				
<b>1 case of BC and a CR with prostate cancer</b>	13.6–19	0.1–7	29	24 (prostate age <60 and BC age <50), 2,3 (Gleason score ≥7), 4,5 (prostate age <55)	III	B
<b>1 case of BC and a CR with pancreatic cancer</b>	19.7–37.5	0.1–12	30,31,32,33,34	3,4, (BC age <50), 2	III	B
<b>1 case of BC and an FDR with individual grade A criteria and no possibility for testing ***</b>		theoretically >50% of IBRCAM of FDR			II	A
<b>Asymptomatic person with individual grade A criteria in an FDR</b>		theoretically 50% of IBRCAM of FDR			II	B

<sup>‡</sup> Combined, personal and family criteria; LOE, level of evidence; CR, close relative, first-degree or second-degree relative; FDR, first-degree relative; 1st/1st: two first-degree relatives; \* BOADICEA, BRCAPRO, PENN II (see Table 5 bis//supplementary data); \*\* in the paternal or maternal side; \*\*\* death or other reason.

discriminate against women with BRCA1 or BRCA2 mutation do not present a discernible family history or meet NCCN [11] or other testing criteria (Table 6).

For women with metastatic breast cancer, olaparib and talazoparib improved both progression-free survival and quality of life as compared with chemotherapy in two phase III randomised trials ([30,31]). Overall survival was not significantly improved in these studies [32,33]. Screening for BRCA1/2 in the metastatic setting is recommended for any TNBC or hormone-resistant breast cancer because personal or family criteria predicting mutation are lacking in 20%–70% of patients (Table 6). In the neoadjuvant setting, PARPi agents are under investigation (ClinicalTrials.gov: NCT03499353) and are not currently recommended outside of the clinical research field.

In metastatic prostate cancer, the PARPi agents, olaparib, rucaparib, niraparib and talazoparib, were found to be effective in phase II or III trials (Table 5). Because almost 50% of BRCA cases occur in patients who do not present family criteria for testing, BRCA testing should be proposed to any person with

metastatic castrate-resistant prostate cancer (Table 6). A fast track process should be proposed to patients with castration-resistant prostate cancer who have already received taxane and abiraterone or enzalutamide because a PARPi, in this case, provides a superior response as compared with other agents, given the results of clinical trials (Table 5, [34]). BRCA tumour genotyping could be proposed as a first approach if coupled with complete information on family and preventive consequences of a germline finding.

In metastatic pancreatic cancer, BRCA testing should be offered to all patients with platinum-sensitive cancer given the results of the POLO study, in which olaparib improved progression-free survival and quality of life of patients with advanced pancreatic cancer, with no disease progression at 16 weeks after platinum initiation [35,36]. Given the rapid evolution of pancreatic cancer, BRCA testing may be proposed as soon as the diagnosis is given. Family criteria could not be used to select patients for BRCA genotyping because 10%–60% of germline mutation carriers with pancreatic cancer do not fit the NCCN criteria (Table 6). Further studies are needed to evaluate whether molecular profiling at the

Table 4  
Rapid BRCA testing for treatment personalisation of primary or metastatic breast cancer.

Treatment personalisation	Option	Treatment phase	Criteria for rapid testing	Personalisation	References
<b>Putative impact on surgery for women considering preventive surgery</b>	mastectomy versus conservative surgery	prior surgery neoadjuvant chemotherapy	age <40 TNBC high IBRCAM newly diagnosed cancer in a family with a known mutation	breast conservative surgery or radical preventive surgery (ipsilateral or bilateral). Both acceptable options.	1
					2 3,4,5,6,7,8
<b>Putative impact on radiation therapy for women considering preventive surgery</b>	no radiation therapy versus radiation therapy	after ipsilateral or bilateral mastectomy	high IBRCAM with age >35, T1/T2, N0, HR+ and HER2-	<ul style="list-style-type: none"> <li>• no PMRT if age &gt;40, HR + Her 2-grade I/II, no LVI, pT1 pN0</li> <li>• PMRT required if age &lt;35, or pN + T3/T4 HER2+ M+</li> <li>• PMRT multidisciplinary discussion if intermediate risk</li> </ul>	9 2
<b>Putative impact on chemotherapy</b>	platinum	neoadjuvant	no evidence of benefit	no recommendations	2 5 6
	platinum versus taxane	metastatic in platinum-naive patient	TNBC or hormone resistant	platinum-containing regimen	10 11,6
<b>Putative impact on targeted therapy</b>	PARPi	neoadjuvant	no evidence of benefit	ongoing trial	12
	PARPi	metastatic	TNBC or hormone resistant	olaparib, talazoparib	13,6,14,2,5

PMRT, post-mastectomy radiation therapy; PARPi, poly(ADP)ribose polymerase inhibitor; HR+, hormone receptor-positive; TNBC, triple-negative breast cancer.

Table 5  
Rapid BRCA testing process for PARPi.

Organ	State	Rapid testing	Drug	Germline or tumour BRCAm, HRD	Approval	Study/Reference
Ovary *	Maintenance (after first line)	Platinum sensitive	olaparib	Tumour or germline	FDA, EMA	SOLO1 <sup>1</sup> (NCT01844986)
		High-grade serous	olaparib plus bevacizumab	Tumour or germline HRD	FDA, EMA	PAOLA <sup>2</sup> (NCT02477644)
		Platinum sensitive High-grade serous or endometrioid	niraparib	All-comers	FDA, EMA	PRIMA <sup>3</sup> (NCT02655016)
	Front line and maintenance	High grade serous or endometrioid	veliparib	Tumour or germline, HRD	FDA UR EMA UR	VELIA <sup>4</sup> (NCT02470585)
		Recurrence	Platinum sensitive High-grade serous or endometrioid	olaparib	Tumour or germline All-comers	FDA, EMA FDA, EMA
	Platinum sensitive High-grade serous or endometrioid		rucaparib	All-comers	FDA, EMA	ARIEL 3 <sup>9,10</sup> (NCT01968213), (NCT01968213)
	Recurrence >2 lines	In patients intolerant to platinum	rucaparib	Tumour or germline	EMA UR	NOVA <sup>11</sup> (NCT01847274) QUADRA <sup>12</sup> (NCT02354586)
Prostate	Metastatic	Castration resistant (who received taxane and abiraterone/enzalutamide)	olaparib	Tumour or germline, HRD	FDA EMA	PROfound <sup>13</sup> (NCT02987543)
			rucaparib niraparib talazoparib	Tumour or germline Tumour or germline All-comers	FDA FDA BTD NA	TRITON 2 <sup>14</sup> (NCT02952534) GALAHAD <sup>15</sup> (NCT02854436) TALAPRO 1/2 <sup>16,17</sup> (NCT03148795), (NCT03395197)
			olaparib	Germline	FDA, EMA	POLO <sup>18</sup> (NCT02184195)
Pancreas	Metastatic Maintenance	Platinum sensitive (with no progression at 16 weeks)	olaparib	Germline	FDA, EMA	OlympiAD <sup>19</sup> (NCT02000622)
Breast	Metastatic or locally advanced	TNBC or HR + HER2- hormone-resistant	olaparib talazoparib	Germline Germline	EMA FDA EMA FDA	EMBRACA <sup>20</sup> (NCT01945775)

HRD, homologous recombination deficiency; BTB Breakthrough Therapy Designation; \*epithelial non-mucinous non-borderline ovarian cancer, tubal or peritoneal carcinoma. UR, Under review; NA, not available.

Table 6  
Likelihood of germline BRCAm in unselected BRCA-related cancer.

Site/Stage	BRCA 1 (%)	BRCA 2 (%)	BRCA 1/2 (%)	References	gBRCAm found although unmet testing criteria* (%)	References
<b>Breast Cancer</b>						
Any disease stage	0.2–4.1	0.8–2.5	1.6–10.7	1,2,3,4,5,6,7,8	20–77	2,9,3,4,5,6,7
Metastatic only	1.1–2.0	1.0–2.9	3.0–4.3	10,11,12	—	—
<b>Prostate Cancer</b>						
Any disease stage	0–1.25	1.1–4.7	1.0–5.9	13,14,15,16	37–64	15,17
Metastatic	0–1.3	4.2–9	4.2–10	13,18,19,20,21,22,23,24,25,26,27,28	44–53	22,23
<b>Pancreatic Cancer</b>						
Any disease stage	0–1.4	1.3–4.2	1.8–7.1	29,30,31,32,33,34,35,36,37,38,39,40	12–57	29,31,33,41,39,40
Metastatic	1.5	1.5	3–7.5	13,42,43,44	—	—
<b>Ovarian Cancer</b>						
Any disease stage	4–13.3	0.6–8	5.8–25.8	8,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59	8–77	48,49,47,46,55,51,56,58

gBRCAm, germline BRCA mutation; \*Testing criteria vary according to the publication, NCCN criteria, family criteria, Ontario criteria, etc.; -, No data available.

time of diagnosis, including BRCAm status, would help decide the first-line chemotherapy (e.g., platinum-containing regimen).

### 3.5. Sequence analysis

BRCA sequence analysis should be performed and reported according to laboratory guidelines such as the American College of Medical Genetics (ACMG) standards ([37] for germline DNA sequencing [38]; for tumour DNA sequencing). For both germline and tumour DNA sequencing and interpretation of results, particular attention should be paid to coverage (at least 100% of exonic sequence and adjacent intronic sequence that may affect the splice site), read depth (at least 30× for germline single nucleotide variant (SNV) DNA sequencing, at least 200× for copy number variant (CNV) DNA sequencing, at least 300× for tumour DNA sequencing), use of the Human Genome Variation Society (HGVS [39]) unambiguous nomenclature for variant designation, and use of well-defined variant classification. For *BRCA1* or *BRCA2* germline variants, classification should be based on variant pathogenicity with respect to a hereditary cancer predisposition syndrome, such as the five-category classification of the ACMG: pathogenic, likely pathogenic, uncertain significance, likely benign, or benign [37]. Standardised terminology and definitions for describing and reporting sequence variation have been set out by the recommendations of the ENIGMA consortium (PMID: 30962250 J Med Genet. 2019 Jun; 56(6):347–357. Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report Amanda B Spurdle 1, Stephanie Greville-Heygate 2, Antonis C Antoniou 3, Melissa Brown 4, Leslie Burke 4, Miguel de la Hoya 5, Susan Domchek 6, Thilo Dörk 7, Helen V Firth 8, Alvaro N Monteiro 9, Arjen Mensenkamp 10, Michael T Parsons 1, Paolo Radice 11, Mark Robson 12, Marc Tischkowitz 13, Emma Tudini 1, Clare Turnbull 14 15, Maaïke Pg Vreeswijk 16, Logan C Walker 17, Sean Tavgian 18 19, Diana M Eccles 2).

For *BRCA1* and *BRCA2* somatic variants, classification should focus on their significance in clinical decision-making with respect to the therapeutic issue (i.e., the 4-category classification of the ACMG: strong clinical significance, potential clinical significance, unknown clinical significance and benign or likely benign variants) [38]. Implementation of techniques and pipelines enabling both SNV and CNV detection should be preferred, optimally by next-generation sequencing. Implementation of identity monitoring should be guaranteed. For appropriate interpretation of tumour DNA sequencing results, specific consideration should be given to the cellularity of the tumour sample (<30% considered as low cellularity and <10% very low cellularity, increasing false-negative results), variant allele

fraction, and variant detection in a normal matched control DNA sample if included.

## 4. Guidelines bottom line

### 4.1. Guideline questions

What are the current indications for BRCA testing in clinical practice?

What is the place for BRCA tumour testing and a fast-track process in treatment personalisation of BRCA-related cancer?

### 4.2. Target population

Individuals with a personal or family risk of a BRCAm (preventive purpose).

### 4.3. Breast cancer patient

Patient with a diagnosis of BRCA-related cancer sensitive to PARPi agents (ovarian, breast, prostate, pancreas).

### 4.4. Target audience

The target audience and intended users of these guidelines are health providers involved in BRCA-related cancers, including geneticists, medical and radiation oncologists, surgeons, organ specialists such as gynaecologists, urologists and gastroenterologists, general practitioners and genetic counsellors.

### 4.5. Guideline aims

Establish clinical guidelines on BRCA testing to (1) identify individuals who may benefit from risk-reducing strategies, (2) update recommendations of testing for

Table 7  
Grade A BRCA testing criteria.

Criteria	
<b>Individual (BC)</b>	Age ≤ 40 Age ≤ 50: bilateral <sup>£</sup> , founder effect <sup>§</sup> Age ≤ 60 triple negative Male
<b>Family history</b>	BC with BC in two FDR* BC with any of individual above criteria in a FDR** Any relative of a known BRCA mutation carrier
<b>Theragnostic</b>	Epithelial ovarian cancer*** Metastatic HR and TN BC Metastatic HR prostate cancer Metastatic platinum-sensitive pancreatic cancer

BC, breast cancer; FDR, first-degree relative; HR, hormone resistant; <sup>£</sup>bilateral BC with one ≤50 years; <sup>§</sup> Ashkenazi Jewish or Icelandic heritages; \* within maternal or paternal side; \*\* anytime possible the affected relative would be the most relevant to test first; \*\*\* also fulfil individual preventive grade A criteria; non-mucinous, including primary peritoneal and fallopian tube; TN, triple negative.

theragnostic purposes with PARPi agents in BRCA-related cancer, (3) provide recommendations for testing for personalised management of early and metastatic breast cancer, and (4) define the place and role of a tumour testing approach and fast-track genotyping and counselling processes.

#### 4.6. Methods

An expert panel consisting of clinical geneticists; medical, radiation and surgical oncologists; molecular geneticists; pathologists; genetic counsellors; patient representatives; ethicists; psychologists; lawyers; and methodologists developed clinical practice guideline recommendations for BRCA testing. These recommendations are based on a combined approach that included a systematic review of the medical literature, evaluation of the IBRCAM (from publications, evaluation by risk assessment models and expert opinion), the theragnostic value in BRCA-related cancer (based on treatment approval for PARPi agents in specific cancer types) and the impact of BRCAM knowledge on the management of early or advanced breast cancer. The overall guideline development process, including the funding of the work, panel formation, management of conflicts of interest, internal and external review, and organisational approval, was guided by procedures derived from the

Guidelines International Network—McMaster Guideline Development Checklist [40].

#### 4.7. Recommendations

##### 1. Preventive

- 1.1. For patients presenting a personal or family history of high IBRCAM (grade A, Table 7), BRCA testing should be offered after genetics information is provided and discussed with a specialist in genetics.
- 1.2. For patients with moderate IBRCAM (grade B, Table 8), testing should be considered taking into account specificities of the family history and personal criteria, and issues should be discussed with the patient in a dedicated and personalised genetic consultation.
- 1.3. Independently of the IBRCAM, testing should be performed in a non-directive manner, and the patient's autonomy and desire to know or to ignore the mutational status must be respected. The individual should make an informed decision with a written consent on whether they want to pursue genetic testing at the dedicated consultation.
- 1.4. For patients with low IBRCAM (grade C) and for whom the mutational status does not have a proven therapeutic value, BRCA testing is not routinely recommended in clinical practice. However, the working group raised the question of the ethical issue of denying access to a BRCA genetic test for informed individuals with low IBRCAM who wish to be tested, given that up to 50% of breast cancer mutation carriers have low IBRCAM. In this situation, genetic counselling before and after the test is highly recommended. The test should be performed in a qualified laboratory fulfilling quality criteria for testing (see below). This option raises unsolved issues of cost-efficiency, medical benefit and testing reimbursement.
- 1.5. Genetic counselling is highly recommended before and after a BRCA predictive test for a known familial mutation.

##### 2. Breast cancer treatment personalisation

- 2.1. For patients with newly diagnosed breast cancer and meeting criteria of high IBRCAM, germline testing (gBRCA) should be considered when BRCAM status could affect the management of breast cancer (Table 4). For women with heredity-associated increased risk of a second cancer, particularly in the context of a cancer-dense family history, TNBC, young age or a relative with a known BRCAM, who are willing to consider the option of risk-reducing surgery, BRCA testing should be offered as a fast-track process after receiving complete information pertaining to the possible outcome of the test. The information should be given by a multidisciplinary team, including an oncologist, surgeon and genetic counsellor, to foster an autonomous choice and optimise the oncological surgical decision and sequence. Appropriately trained non-geneticists involved in breast cancer such as oncologists and surgeons could give adequate information in coordination with genetic professionals.
- 2.2. For metastatic breast cancer patients requiring chemotherapy, gBRCAM testing is recommended

Table 8  
Grade B BRCA testing criteria.

Criteria
<b>Individual (BC)</b>
<ul style="list-style-type: none"> <li>• Age 41-45</li> <li>• TNBC age &gt;60</li> <li>• Bilateral (first after age 50)</li> <li>• BC &gt;50 with founder effect*</li> </ul>
<b>Family history or combined</b>
<ul style="list-style-type: none"> <li>• BC with 2 cases of BC in a second- or third-degree relative</li> <li>• BC with individual grade A criteria (TNBC, age ≤ 40, male, ovarian cancer) in a second- or third-degree relative</li> <li>• BC and 1 case of BC in first-degree relative with one age ≤ 50</li> <li>• BC and a bilateral BC in first-degree relative (first after age 50)</li> <li>• BC and 1 case of prostate cancer (Gleason score ≥ 7, metastatic or age ≤ 60) in an FDR</li> <li>• BC and 1 case of pancreas cancer in an FDR</li> <li>• BC with association of 2 cases of prostate (Gleason score ≥ 7, metastatic or age ≤ 60 years), pancreas or melanoma cancer in a CR</li> <li>• Prostate or pancreatic cancer with AJ or Icelandic heritage</li> <li>• Family history<sup>a</sup> of pancreatic and/or prostate cancer</li> <li>• Person with an FDR with one of individual grade A criteria and no possibility for testing<sup>b</sup></li> </ul>

CR, close relative; FDR, first-degree relative; If not specify BC, breast cancer any age. \* founder effect: Ashkenazi Jewish or Icelandic heritages.

<sup>a</sup> Association of two or more of these types of cancer in a CR on maternal or paternal side.

<sup>b</sup> Death or other reason.

because platinum chemotherapy should be preferred to taxane in platinum-naïve patients.

- 2.3. In HER2-negative metastatic breast cancer, gBRCAm testing is recommended because olaparib or talazoparib should be offered as an alternative to first-to-third-line chemotherapy for women with gBRCAm.
3. PARPi
- 3.1. BRCA testing should be offered for PARPi therapeutic purposes to patients with HER2-negative metastatic breast and castrate-resistant prostate cancer, platinum-sensitive metastatic pancreatic cancer and newly diagnosed FIGO stage III/IV or recurrent high-grade epithelial ovarian cancer in a fast-track process after specific genetic information is provided.
  - 3.2. For targeted therapy with PARPi agents, BRCA testing is recommended regardless of moderate or high IBRCam criteria because 10%–75% of patients with breast, ovarian, prostate or pancreatic cancer, and gBRCAm do not fulfil these criteria (Table 6).
  - 3.3. Epithelial ovarian cancer fulfils criteria of high IBRCam for risk-reducing purposes and major therapeutic value. Therefore, gBRCA testing should be offered to any woman with epithelial non-borderline non-mucinous ovarian cancer at the time of diagnosis in a fast-track process. Additional tumour testing should be proposed to ovarian cancer patients who do not carry gBRCAm.
  - 3.4. Appropriately trained non-geneticists involved in cancer care such as oncologists and surgeons could give adequate initial information in coordination with a multidisciplinary team, including geneticists.
4. Tumour testing
- 4.1. When tumour testing for therapeutic purposes is the preferred initial approach, the patient should be aware of inherited genetic aspects, including family and prevention issues that might emerge from genetic tumour testing, because most tumour BRCAm findings reflect a germline predisposition. Thus, genetic information and informed consent are required before any BRCA tumour testing. In case of therapeutic value, the information should be given by trained healthcare providers such as oncologists familiar with the genetic diagnosis and management of hereditary breast cancer, working in conjunction with a genetic consultation.
  - 4.2. For appropriate interpretation of tumour DNA sequencing results, specific consideration should be given to the cellularity of tumour sample, depth of coverage, ability to detect long-scale rearrangement and variant allele fraction. Techniques and pipelines enabling both SNV and CNV detection such as next-generation sequencing should be preferred.
  - 4.3. Germline testing should be offered to any patient with an identified pathogenic or likely pathogenic tumour BRCA mutation.
  - 4.4. Educational programs should be developed to increase the awareness and training of healthcare providers in oncology, particularly oncologists, surgeons, organ specialists and patient advocacy representatives, to improve their skills to provide adequate explanations for BRCA testing for therapeutic purposes and personalised care according to the genetic results.

## 5. General recommendations

- 5.1. Clinical decisions, including preventive issues, management of breast cancer or PARPi treatment, should be based on pathogenic or likely pathogenic variants but not variants of unknown significance (VUS).
- 5.2. BRCA sequence analysis should be performed and reported according to laboratory guidelines. For both germline and tumour DNA sequencing and interpretation of results, particular attention should be paid to sequence coverage (at least 100% of exonic sequence and intronic sequence adjacent to the splice site) and read coverage (at least 30× for SNV and 200× for CNV in germline DNA sequencing, at least 300× for tumour DNA sequencing). Results should use an unambiguous nomenclature for variant designation and classification (HGVS, ACMG).
- 5.3. For germline or tumour BRCA genetic testing for therapeutic use, the information should be given by a clinician trained and aware of genetics, including the interpretation of results, regulations and risk-reducing strategies. The information given to the patient may include the medical implications of a positive, negative or non-informative result (i.e., VUS); the risk of transmission of genetic predisposition to offspring and family relatives (and according to regulations of certain countries in Europe, the legal obligation to transmit the information to close relatives); and the risk and benefit of risk-reducing strategies and the psychological consequences of knowing a genetic predisposition.

## 5. Discussion

*BRCA1* and *BRCA2* gene mutations account for most actionable genetic breast cancer predispositions and are increasingly used for personalised breast cancer management and PARPi therapy of BRCA-related cancer. Thus, we propose updated guidelines for *BRCA* testing. Preventive and therapeutic indications are now overlapping in many situations, as in ovarian cancer or metastatic breast cancer. Thus, BRCA testing should be considered in a global and integrative way so that healthcare providers involved in both cancer care and genetics can clarify and standardise the appropriate process and timing of BRCA testing for all patients. With this aim, we introduce a methodology of recommendations based on expert consensus, integrating published data on IBRCam and their respective levels of evidence, evaluation of IBRCam by risk model assessment as well as the therapeutic value of BRCAm for managing BRCA-related cancer.

Of note, epithelial ovarian cancer is the most powerful predictor of IBRCam. Also, BRCAm in ovarian cancer offers the most actionable context for both preventive and therapeutic purposes. This point still needs to be universally communicated to healthcare providers and to professionals involved in managing ovarian cancer because recent data show a lack of testing in patients with ovarian cancer [41].

Although the burgeoning knowledge of hereditary breast and ovarian cancer (HBOC) and the development

of next-generation sequencing have prompted the use of multigene panels that include *TP53*, *PALB2*, *PTEN*, *CDH1*, and *STK11*, *BRCA1* and *BRCA2* gene mutations account for the vast majority of the actionable and identifiable hereditary syndromes [42–44]. Moreover, many other actionable genes involved in HBOC (i.e. *TP53*, *PTEN*, *CDH1* and *STK11*) are often responsible for specific personal and family characteristics that differ from criteria for *BRCA* testing. Therefore, guidelines for *BRCA* testing should be clarified independently of other considerations. However, multigene panel genotyping is useful in *BRCA*-negative familial syndrome. Mutations of *PALB2*, *RAD51C* and other genes are currently under investigation to detect PARPi sensitivity but are not yet approved in *BRCA*-related cancer. The human recombination deficiency (HRD) that included tBRCAM and gBRCAM is approved as a predictive marker of PARPi sensitivity in ovarian cancer and studied with different approaches in other *BRCA*-related cancer. Further recommendations are needed for clinicians on HRD used as a predictive marker of PARPi sensitivity. Here, we focused on specific criteria that drive a clinical, non-systematic and personalised recommendation of *BRCA* testing for any individual with a family history or affected by *BRCA*-related cancer.

From abundant literature, personal parameters related to breast cancer, such as TNBC, male breast cancer, early-onset breast cancer, or bilateral breast cancer, have been identified as predictors of a high probability of harbouring *BRCA1* or *BRCA2* mutations. The founder effect is another parameter that significantly increases the IBRCAM. For women with breast cancer who are of Ashkenazi or Icelandic heritage, the IBRCAM varies widely according to the study and population (from 4.5% to 25%; Table 2b). When considering subgroups of early-onset, TNBC and male breast cancer in individuals of Ashkenazi or Icelandic ethnicity, the IBRCAM is increased to more than 10%. Ashkenazi or Icelandic heritage in other situations received a grade B recommendation for testing outside these subgroups, except for Ashkenazi Jewish and Icelandic women with breast cancer diagnosed before age 50 years. Ashkenazi or Icelandic heritage in a woman with any grade B personal or family criteria should be considered for testing because this factor significantly increases the IBRCAM.

Most combined and family criteria proposed in guidelines are based on clinical studies with a low level of evidence. For most of these criteria, only subgroup analyses of studies were available, and for some, no data were available in our search. Moreover, most published data are devoted to the selection bias of women referred for genetic counselling and undergoing *BRCA* testing. In situations of combined criteria for which clinical data are lacking, a risk assessment model could provide a helpful estimate of the IBRCAM. However, as reported

previously, the estimation varies widely among models [45] and may not be appropriate to discriminate some situations such as triple-negative phenotype, discrimination of risk according to relative closeness, ability to score single criteria, integrating prostate or pancreas cancer affecting relatives, etc. Because family or combined situations could not be exhaustively addressed by a literature search and/or estimates by models, IBRCAM >2.5% was assumed for some items such as ‘BC with  $\geq 2$  prostate, pancreatic or melanoma cancer cases in close relatives’ or ‘family history of pancreatic cancer and/or prostate cancer ( $\geq 2$  cancer cases in first-, second- or third-degree relatives)’. With the complexity and a high number of combinations of parameters, the evaluation of IBRCAM in each situation should be addressed and discussed in a dedicated genetic and personalised consultation.

Because of the clinical benefits of PARPi in *BRCA*-related cancer, the lack of timely identification of a BRCAM represents a lost opportunity for patients. Between 30% and 50% of patients with ovarian cancer or metastatic prostate, pancreatic or breast cancer do not fulfil personal or family criteria for preventive *BRCA* testing; thus, family history or personal criteria for testing cannot be retained to select patients who require testing. Of note, the incidence of BRCAM in metastatic prostate, pancreatic and breast cancer are in the range of grade B recommendations for testing for preventive purposes (2.5%–7.5%).

In these guidelines, when the IBRCAM is estimated at <2.5% and the mutational status does not have therapeutic value, *BRCA* testing is not routinely recommended in clinical practice (expert agreement). The benefit of genetic testing is not established in women whose personal or family history suggest low risk for mutations in *BRCA1* and *BRCA2* genes, and the US Preventive Services Task Force found adequate evidence that this benefit is small to none (ref Task Force). However, in the study by Buchanan *et al.*, some women with *BRCA1* or *BRCA2* mutation found in the UK genome projects without any personal/family criteria of testing benefitted from screening [46]. Other studies suggest that screening may be beneficial in the general population or in women with breast cancer, particularly in populations with a high rate of predominant mutations [47,48]. The cost-effectiveness of *BRCA* testing is also debated in the low-risk or general population [49,50]. Further studies are required to state the medical benefit and cost-effectiveness of offering *BRCA* testing in populations with low IBRCAM and refining this cut-off. Overall, 20%–77% of BRCAM carriers in breast cancer do not fulfil testing criteria (Table 6), so strictly limiting access to genetic testing to people with high or moderate risk criteria and denying access to those with low risk who wish to be tested is questionable. The access of a person willing to undergo the test after genetic counselling and being given appropriate

information about the benefits and risks of testing raises a host of unanswered questions in terms of ethics, regulation and economics. The Royal Marsden/ICR proposed that individuals not meeting any of the eligibility criteria could have a self-funded test. Other healthcare payers may be involved. The issue of testing low-risk individuals should be addressed in a personalised way according to the regional health regulations, funding and insurance policies. For testing low-risk patients, the working group recommended dedicated genetic consultation before and after the test, with complete information (including psychological impact, risk-reducing strategy and familial consequences of the test). Attention should be paid to the quality of the analysis, as described in our guidelines.

Genetic counselling by a genetics professional genetics is recommended before and after a genetic test for an inherited breast/ovarian cancer syndrome related to BRCA and performed for preventive purposes. For theragnostic purposes, the information should be given by a clinician (physician or surgeon) who is trained, aware of genetics regulation, comfortable with interpreting results of a genetic test, and able to give appropriate information on risk-reducing strategies. The information should include the medical implications of a positive, negative or non-informative result (e.g., VUS); the risk of transmission of the genetic predisposition allele to an offspring and other family members (and according to regulations of certain countries in Europe, the juridical obligation to transmit the information to close relatives), the risk and benefit of risk-reducing strategies, and the psychological consequence of knowing the precise risk of genetic predisposition-associated cancer. Increasing numbers of surgeons and oncologists are becoming aware of these issues, and recent publications such as the ENGAGE results show that an oncologist-led BRCAm testing process in ovarian cancer is feasible [51].

If tumour testing for theragnostic purposes is preferred as the initial approach, the patient should be aware of the same family and prevention issues because most of the tumour mutation findings will be related to a germline predisposition [8,17]. Therefore, informed consent and genetic information are still required before any BRCA tumour testing, and patients should be aware that the results may have extra-therapeutic medical issues for themselves and their relatives. We and others previously reported clinical practice considerations and schemes for managing germline findings in somatic analysis, including written informed consent and a multidisciplinary approach involving an oncologist, molecular biologist/pathologist and geneticist for germline findings [8,16,17]. At any time of the somatic analysis, a patient may have access to a consultation with a geneticist if additional information is required. These recommendations should be regularly updated according to the knowledge evolution about cancer risk,

target therapies with PARPi agents or other agents, and the level of evidence.

These integrative and updated guidelines may help clinicians standardise and optimise BRCA testing practices for both preventive and therapeutic purposes.

### Conflicts of interest

The development of these guidelines was wholly funded by SFMPP. The panelists received no payments. The complete CoI for researchers who contributed to the guidelines are provided in supplementary data. Categories for disclosure of CoI include employment; leadership; stock or other ownership; honoraria, consulting or advisory role; speaker's bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships.

### Acknowledgements

The authors acknowledge the contribution of patient advocacy from BRCA France and *Sapins de Noël des créateurs* associations.

### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ejca.2020.12.023>.

### References

- [1] Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003;72:1117–30.
- [2] Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA* 2017;317:2402–16.
- [3] Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, et al. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests. *Breast Canc Res Treat* 2013;141:135–44.
- [4] Guo F, Hirth JM, Lin Y-L, Richardson G, Levine L, Berenson AB, et al. Use of BRCA mutation test in the U.S., 2004–2014. *Am J Prev Med* 2017;52:702–9.
- [5] Liede A, Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer, Mansfield CA, Metcalfe KA, Price MA, Snyder C, et al. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. *Breast Canc Res Treat* 2017;165:433–44. <https://doi.org/10.1007/s10549-017-4332-3>.
- [6] Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. *J Clin Oncol* 2020;38:1222–45.
- [7] Nevriere Z, De La Motte Rouge T, Floquet A, Johnson A, Berthet P, Joly F. How and when to refer patients for oncogenetic



- counseling in the era of PARP inhibitors. *Ther Adv Med Oncol* 2020;12: 1758835919897530.
- [8] Capoluongo E, Scambia G, Nabholz J-M. Main implications related to the switch to 1/2 tumor testing in ovarian cancer patients: a proposal of a consensus. *Oncotarget* 2018;9: 19463–8.
- [9] Forbes C, Fayter D, de Kock S, Quek RGW. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. *Canc Manag Res* 2019;11:2321–37. <https://doi.org/10.2147/cmar.s189627>.
- [10] Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. *Br J Canc* 2018;119:141–52.
- [11] Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020. *J Natl Compr Canc Netw* 2020;18:380–91.
- [12] Tung NM, Boughhey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, et al. Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline. *J Clin Oncol* 2020;38:2080–106.
- [13] US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive Services Task Force recommendation statement. *JAMA* 2019;322:652–65.
- [14] Runowicz CD, Leach CR, Lynn Henry N, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. *J Clin Oncol* 2016;34:611–35. <https://doi.org/10.1200/jco.2015.64.3809>.
- [15] Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. UK: London: National Institute for Health and Care Excellence; 2020.
- [16] Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, et al. Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. *Eur J Hum Genet* 2018;26:1732–42.
- [17] Pujol P, De La Motte Rouge T, Penault-Llorca F. From targeting somatic mutations to finding inherited cancer predispositions: the other side of the coin. *Diagnostics* 2019;9. <https://doi.org/10.3390/diagnostics9030083>.
- [18] Pujol P, Fodil-Chérif S, Mandel JL, Baertschi B, Sanlaville D, Zarca D, et al. Réflexions éthiques sur le dépistage génétique préconceptionnel en population générale : le débat français et l'avis de la Société Française de Médecine Prédictive et Personnalisée. *Ethics, Medicine and Public Health* 2020;12:100439. <https://doi.org/10.1016/j.jemep.2019.100439>.
- [19] Guideline development checklist n.d. <http://cebgrade.mcmaster.ca/guidecheck.html> [accessed 1 September 2020].
- [20] Welcome to G-I-N — guidelines international Network n.d. <https://g-i-n.net/> [accessed 1 September 2020].
- [21] BRCAPRO n.d. <https://projects.iq.harvard.edu/bayesmendel/brcapro> [accessed 31 August 2020].
- [22] Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. *J Clin Oncol* 2002;20:2701–12. <https://doi.org/10.1200/jco.2002.05.121>.
- [23] BOADICEA web application - centre for cancer genetic epidemiology n.d. <https://cce.medschl.cam.ac.uk/boadicea/boadicea-web-application/> [accessed 31 August 2020].
- [24] Antoniou AC, Pharoah PPD, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. *Br J Canc* 2004;91:1580–90. <https://doi.org/10.1038/sj.bjc.6602175>.
- [25] Couch FJ, DeShano ML, Anne Blackwood M, Calzone K, Stopfer J, Campeau L, et al. BRCA1 Mutations in women attending clinics that evaluate the risk of breast cancer. *N Engl J Med* 1997;336:1409–15. <https://doi.org/10.1056/nejm199705153362002>.
- [26] Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)†. *Ann Oncol* 2018;29: 1634–57.
- [27] OncologyPRO. Making a difference for advanced breast cancer patients n.d. <https://oncologypro.esmo.org/meeting-resources/eso-esmo-advanced-breast-cancer-fifth-international-consensus-conference-abc5/making-a-difference-for-advanced-breast-cancer-patients> [accessed 1 September 2020].
- [28] Institut National Du Cancer. Thésaurus - Femmes porteuses d'une mutation de BRCA1 ou BRCA2/Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque - ref : RECOBRCATHES17 n.d. <http://www.e-cancer.fr/> [accessed 28 August 2020].
- [29] Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. *Nat Med* 2018;24:628–37.
- [30] Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med* 2017;377:523–33.
- [31] Litton J, Rugo HS, Ettl J, Hurvitz S, Gonçalves A, Lee K-H, et al. Abstract GS6-07: EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. General Session Abstracts. American Association for Cancer Research; 2018. p. GS6-07–GS6-07.
- [32] Program Planner n.d. <https://www.abstractsonline.com/pp8/#!/9045/presentation/10773> [accessed 1 September 2020].
- [33] Robson M, Domchek S. Broad application of multigene panel testing for breast cancer susceptibility-Pandora's box is opening wider. *JAMA Oncol* 2019. <https://doi.org/10.1001/jamaoncol.2019.4004>.
- [34] Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, et al. Implementation of germline testing for prostate cancer: philadelphia prostate cancer consensus conference 2019. *J Clin Oncol* 2020;38:2798–811.
- [35] Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. *N Engl J Med* 2019;381: 317–27. <https://doi.org/10.1056/nejmoa1903387>.
- [36] Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla Mercade T, Hall MJ, et al. POLO: health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC). *Ann Oncol* 2019;30:v254–5. <https://doi.org/10.1093/annonc/mdz247.003>.
- [37] on behalf of the ACMG Laboratory Quality Assurance Committee, Richards S, Aziz N, Bale S, Bick D, Das S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. *Genet Med* 2015;17:405–23.
- [38] Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists. *J Mol Diagn* 2017;19:4–23.
- [39] Describing sequence variants n.d. <http://www.hgvs.org/mutnomen> [accessed 1 September 2020].
- [40] Guideline development checklist n.d. <http://cebgrade.mcmaster.ca/guidecheck.html> [accessed 1 September 2020].

- [41] Dewdney S, Potter D, Haidle JL, Hulick PJ, Riffon M, Monzon FA, et al. Low rates of BRCA1 and BRCA2 testing for patients with ovarian cancer in ASCO's CancerLinQ, a real-world database. *J Clin Oncol* 2020;38. [https://doi.org/10.1200/jco.2020.38.15\\_suppl.6041](https://doi.org/10.1200/jco.2020.38.15_suppl.6041). 6041–6041.
- [42] Huang K-L, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic germline variants in 10,389 adult cancers. *Cell* 2018;173:355–70.e14.
- [43] Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. *Cancer* 2017;123:1721–30.
- [44] Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol* 2017;3:1190–6.
- [45] Panchal SM, Ennis M, Canon S, Bordeleau LJ. Selecting a BRCA risk assessment model for use in a familial cancer clinic. *BMC Med Genet* 2008;9:116.
- [46] Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, et al. Exome sequencing-based screening for BRCA1/2 expected pathogenic variants among adult biobank participants. *JAMA Netw Open* 2018;1:e182140.
- [47] King M-C, Lahad A, Levy-Lahad E. Proposed shift in screening for breast cancer—reply. *JAMA* 2015;313:525–6.
- [48] Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. *Proc Natl Acad Sci U S A* 2014;111:14205–10.
- [49] Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. *JAMA Oncol* 2019. <https://doi.org/10.1001/jamaoncol.2019.3323>.
- [50] Tuffaha HW, Mitchell A, Ward RL, Connelly L, Butler JRG, Norris S, et al. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. *Genet Med* 2018;20:985–94.
- [51] Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, et al. Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer. *J Clin Oncol* 2018;36:1300–7.